BR112021021626A2 - Proteína selecionada a partir do grupo que consiste em chrdll, fam3c, fam3b e fragmentos da mesma ou um polinucleotídeo que codifica a mesma, proteína ou polinucleotídeo para uso, vetor para uso no tratamento ou redução do risco de doença cardíaca, e, composição farmacêutica - Google Patents

Proteína selecionada a partir do grupo que consiste em chrdll, fam3c, fam3b e fragmentos da mesma ou um polinucleotídeo que codifica a mesma, proteína ou polinucleotídeo para uso, vetor para uso no tratamento ou redução do risco de doença cardíaca, e, composição farmacêutica

Info

Publication number
BR112021021626A2
BR112021021626A2 BR112021021626A BR112021021626A BR112021021626A2 BR 112021021626 A2 BR112021021626 A2 BR 112021021626A2 BR 112021021626 A BR112021021626 A BR 112021021626A BR 112021021626 A BR112021021626 A BR 112021021626A BR 112021021626 A2 BR112021021626 A2 BR 112021021626A2
Authority
BR
Brazil
Prior art keywords
protein
polynucleotide
chrdll
fam3b
fam3c
Prior art date
Application number
BR112021021626A
Other languages
English (en)
Portuguese (pt)
Inventor
Francesca Bortolotti
Giulia Ruozi
Mauro Giacca
Original Assignee
Int Centre For Genetic Engineering And Biotechnology Icgeb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Centre For Genetic Engineering And Biotechnology Icgeb filed Critical Int Centre For Genetic Engineering And Biotechnology Icgeb
Publication of BR112021021626A2 publication Critical patent/BR112021021626A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Dermatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
BR112021021626A 2019-04-30 2020-04-30 Proteína selecionada a partir do grupo que consiste em chrdll, fam3c, fam3b e fragmentos da mesma ou um polinucleotídeo que codifica a mesma, proteína ou polinucleotídeo para uso, vetor para uso no tratamento ou redução do risco de doença cardíaca, e, composição farmacêutica BR112021021626A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1906052.4A GB201906052D0 (en) 2019-04-30 2019-04-30 Proteins with cardioprotective activity
PCT/EP2020/062156 WO2020221906A1 (en) 2019-04-30 2020-04-30 Proteins with cardioprotective activity

Publications (1)

Publication Number Publication Date
BR112021021626A2 true BR112021021626A2 (pt) 2021-12-21

Family

ID=66589570

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021626A BR112021021626A2 (pt) 2019-04-30 2020-04-30 Proteína selecionada a partir do grupo que consiste em chrdll, fam3c, fam3b e fragmentos da mesma ou um polinucleotídeo que codifica a mesma, proteína ou polinucleotídeo para uso, vetor para uso no tratamento ou redução do risco de doença cardíaca, e, composição farmacêutica

Country Status (25)

Country Link
US (3) US12569574B2 (enExample)
EP (2) EP3962534B1 (enExample)
JP (2) JP7707075B2 (enExample)
KR (2) KR20220027829A (enExample)
CN (2) CN120518738A (enExample)
AU (1) AU2020267029A1 (enExample)
BR (1) BR112021021626A2 (enExample)
CA (1) CA3137662A1 (enExample)
DK (1) DK3962534T3 (enExample)
ES (1) ES2975422T3 (enExample)
FI (1) FI3962534T3 (enExample)
GB (1) GB201906052D0 (enExample)
HR (1) HRP20240441T1 (enExample)
HU (1) HUE066324T2 (enExample)
IL (1) IL287525A (enExample)
LT (1) LT3962534T (enExample)
MX (2) MX2021013298A (enExample)
PL (1) PL3962534T3 (enExample)
PT (1) PT3962534T (enExample)
RS (1) RS65469B1 (enExample)
SG (1) SG11202111267WA (enExample)
SI (1) SI3962534T1 (enExample)
SM (1) SMT202400151T1 (enExample)
WO (1) WO2020221906A1 (enExample)
ZA (2) ZA202107778B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201906052D0 (en) 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity
WO2025253097A1 (en) * 2024-06-03 2025-12-11 Forcefield Therapeutics Limited Proteins with cardiopreservation activity
GB202415505D0 (en) * 2024-10-21 2024-12-04 King S College London Lipid nanoparticles for cardiac protection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416538A1 (en) * 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2003265867A1 (en) * 2002-08-29 2004-10-18 Oxford Glycosciences (Uk) Ltd. A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use
US7312079B1 (en) * 2005-10-06 2007-12-25 Lexicon Pharmaceuticals, Inc. Variants of FAM3C
DK2623605T3 (en) 2007-04-09 2019-03-25 Univ Florida RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF
US20130136738A1 (en) * 2010-01-26 2013-05-30 Zhaodan Cao Methods of Treating Glucose Metabolism Disorders
EP2533796A4 (en) * 2010-02-12 2013-12-04 Ngm Biopharmaceuticals Inc METHOD FOR THE TREATMENT OF GLUCOSE TISSUE CHANGES
KR102248900B1 (ko) 2011-09-30 2021-05-07 소마로직, 인크. 심혈관 위험 사건 예측 및 그것의 용도
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
EP2981334A4 (en) * 2013-04-03 2016-11-23 Univ California COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ACTIVITY
US20170209621A1 (en) * 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Use of chordin-like 1 or collagen vi with mesenchymal stem cells
KR102022021B1 (ko) * 2018-01-10 2019-09-18 한국과학기술연구원 심혈관 질환의 진단을 위한 바이오마커 및 이의 용도
GB201906052D0 (en) 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity

Also Published As

Publication number Publication date
CN120518738A (zh) 2025-08-22
JP2025107171A (ja) 2025-07-17
LT3962534T (lt) 2024-05-27
CN113795504B (zh) 2025-05-06
EP3962534A1 (en) 2022-03-09
MX2021013298A (es) 2021-12-10
EP4389211A2 (en) 2024-06-26
US20250057982A1 (en) 2025-02-20
SG11202111267WA (en) 2021-11-29
WO2020221906A1 (en) 2020-11-05
JP2022530168A (ja) 2022-06-27
RS65469B1 (sr) 2024-05-31
DK3962534T3 (da) 2024-04-15
AU2020267029A1 (en) 2021-12-23
US20220193260A1 (en) 2022-06-23
ES2975422T3 (es) 2024-07-05
ZA202309540B (en) 2025-12-17
SI3962534T1 (sl) 2024-08-30
EP4389211A3 (en) 2024-08-28
FI3962534T3 (fi) 2024-04-17
US12121594B2 (en) 2024-10-22
PT3962534T (pt) 2024-04-03
US12569574B2 (en) 2026-03-10
JP7707075B2 (ja) 2025-07-14
EP3962534B1 (en) 2024-02-21
GB201906052D0 (en) 2019-06-12
HRP20240441T1 (hr) 2024-06-21
IL287525A (en) 2021-12-01
CN113795504A (zh) 2021-12-14
CA3137662A1 (en) 2020-11-05
US20220387625A1 (en) 2022-12-08
HUE066324T2 (hu) 2024-07-28
SMT202400151T1 (it) 2024-05-14
MX2026002607A (es) 2026-04-01
ZA202107778B (en) 2024-02-28
KR20260099232A (ko) 2026-06-26
PL3962534T3 (pl) 2024-06-10
KR20220027829A (ko) 2022-03-08

Similar Documents

Publication Publication Date Title
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
BR112018006531A2 (pt) proteína isolada de ligação ao antígeno (abp), polinucleotídeo isolado, vetor, célula hospedeira, método para produzir uma proteína isolada de ligação ao antígeno (abp), composição farmacêutica, método para tratar ou prevenir uma doença ou condição num sujeito em necessidade deste, método para modular uma resposta imune num indivíduo em necessidade deste e kit
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
BR112018068906A2 (pt) composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112018000835A2 (pt) molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
BR112018008746A2 (pt) composições e métodos para a inibição de atividade de arginase
BR112021021921A2 (pt) Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica
BR112016017041A2 (pt) Proteína isolada tendo atividade de fosfatase, polinucleotídeo, vetor, célula hospedeira, método para produzir uma proteína e composição
BR112018074978A2 (pt) anticorpos para alfa-sinucleína e usos dos mesmos
BR112012012918A2 (pt) agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes.
BR112017008805A2 (pt) tratamento de córnea usando laminina
ZA202110111B (en) Methods and compositions for treating liver disorders
BR112021024634A2 (pt) Método de tratamento ou prevenção de um distúrbio, doença ou condição aliviada pela estimulação ou modulação da expressão de colágeno
MX2020011100A (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar.
BR112017005235A2 (pt) vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
BR112018010255A2 (pt) antibióticos macrocíclicos de amplo espectro
BR112018010160A2 (pt) inibidor da c1 esterase humana recombinante e usos do mesmo
BR112022012278A2 (pt) Combinações
BR112019007928A2 (pt) conjugados de bacitracina-oligômero de alginato
BR112018014762A2 (pt) método de tratamento da doença de alzheimer (da) precoce
BR112018010267A2 (pt) antibióticos macrocíclicos de amplo espectro
BR112019003912A2 (pt) composição, método para criação de um hidrogel, matriz, hidrogel, método para indução da formação ou regeneração de um tecido neuronal, método para tratamento de uma lesão do nervo e método para prevenção ou tratamento de choque neurogênico após lesão do nervo
BR112018006572A2 (pt) terapia de combinação racional para o tratamento de câncer
MX2026002607A (es) Proteinas con actividad cardioprotectora